AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioSig Technologies' 15min Chart Sees MACD Death Cross and KDJ Death Cross
ByAinvest
Thursday, Sep 11, 2025 2:38 pm ET1min read
BioSig Technologies's 15-minute chart has recently triggered a MACD Death Cross and a KDJ Death Cross, as of September 11th, 2025, at 14:30. This suggests that the stock price has the potential to continue its downward trajectory, with momentum shifting towards the downside. Furthermore, this could lead to a further decrease in stock price.
BioSig Technologies, Inc. (NASDAQ: BSGM), which recently merged with Streamex Exchange Corporation (together, "BSGM" or the "Company"), has announced a significant corporate rebranding. Effective at 12:01 am Eastern Time on Friday, September 12, 2025, the company will change its name to Streamex Corp. and its trading symbol to "STEX". This rebranding coincides with the stock's recent technical indicators suggesting a potential downward trend.As of September 12, 2025, all Company stock trading, filings, and market-related information will be reported under the new symbol "STEX". The Company’s CUSIP number will remain unchanged, and no action is required from shareholders. No other aspects of the Company’s corporate structure or operations are impacted by the ticker symbol change.
Streamex is a Real World Asset (RWA) tokenization company with Institutional-grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold-denominated treasury and tokenization technology, Streamex aims to modernize the commodities market. BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform, which delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.
According to technical indicators, BioSig Technologies' 15-minute chart triggered a MACD Death Cross and a KDJ Death Cross as of September 11, 2025, at 14:30. These indicators suggest that the stock price has the potential to continue its downward trajectory, with momentum shifting towards the downside. This could lead to a further decrease in stock price.
The Company's press release also includes forward-looking statements, which are subject to various known and unknown risks and uncertainties. Investors are advised to review the Company's filings with the Securities and Exchange Commission for a discussion of other risks and uncertainties, including the section titled "Risk Factors" in the Annual Report on Form 10-K, filed on April 15, 2025 [1].
For more information, please contact:
- Adele Carey, Alliance Advisors Investor Relations, acarey@allianceadvisors.com
- Henry McPhie, CEO of BioSig, Co-Founder of Streamex, contact@Streamex.com
Visit [Streamex.com](https://www.streamex.com/) and [@Streamex](https://x.com/streamex) for more details.
[1]: BioSig and Streamex, "BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.", September 10, 2025.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet